These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 16648500)

  • 1. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.
    Donskov F; von der Maase H
    J Clin Oncol; 2006 May; 24(13):1997-2005. PubMed ID: 16648500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
    Donskov F
    Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.
    Jensen HK; Donskov F; Marcussen N; Nordsmark M; Lundbeck F; von der Maase H
    J Clin Oncol; 2009 Oct; 27(28):4709-17. PubMed ID: 19720929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of intratumoral natural killer cells in gastric carcinoma.
    Ishigami S; Natsugoe S; Tokuda K; Nakajo A; Che X; Iwashige H; Aridome K; Hokita S; Aikou T
    Cancer; 2000 Feb; 88(3):577-83. PubMed ID: 10649250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
    Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
    J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.
    Mekhail TM; Abou-Jawde RM; Boumerhi G; Malhi S; Wood L; Elson P; Bukowski R
    J Clin Oncol; 2005 Feb; 23(4):832-41. PubMed ID: 15681528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma.
    Culine S; Bekradda M; Kramar A; Rey A; Escudier B; Droz JP
    Cancer; 1998 Dec; 83(12):2548-53. PubMed ID: 9874462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
    Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
    J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.
    Nakayama K; Tannir NM; Liu P; Wathen JK; Cheng YC; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):975-85. PubMed ID: 17640602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factors in patients with metastatic renal cell carcinoma].
    Inoue R; Takahashi A; Takasugi S; Masumori N; Tsukamoto T; Hasegawa T
    Hinyokika Kiyo; 2010 Feb; 56(2):75-9. PubMed ID: 20185990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.